Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis has opened a new research institute, the Novartis Vaccines Institute for Global Health or NVGH in Siena, with a nonprofit mission to exclusively focus on the development of vaccines for diseases of the developing world.
Subscribe to our email newsletter
The NVGH’s goal is to address the unmet medical need for vaccines for diseases of the developing world by researching vaccines specifically tailored for developing country needs and introducing them first in those countries. The NVGH is a public private partnership and will also collaborate with external organizations to build strength in resources. The institute will be headed by Allan Saul, who has nearly 30 years of experience in translational R&D.
Daniel Vasella, chairman and CEO of Novartis, said: “NVGH reinforces the Novartis commitment to R&D for neglected diseases, and will potentially bring innovative vaccines to the patients who may need it most.”